The DOI matches its Crossref record.
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization
Abstract
A diversity of nicotinic acetylcholine receptor (nAChR) subtypes has been identified in mammalian brain using recombinant DNA technology. Alterations in the activity of these acetylcholinegated ion channels have been implicated in a number of central nervous system disorders including Alzheimer's disease (AD). The potential therapeutic usefulness of (-)-nicotine [(S)-3-(1-methyl-2-pyrrolidinyl) pyridine], the prototypic agonist at nAChRs, is severely limited by side effects that are the result of activation of both cholinergic and noncholinergic pathways in the central and peripheral nervous systems. This study sought to determine the in vitro selectivity of (S)-3-methyl-5-(1methyl-2-pyrrolidinyl)isoxazole (ABT 418), a novel analog of (-)-nicotine in which the pyridine ring was replaced with an isoxazole bioisotere, to activate nAChRs. ABT 418 was a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain (Ki = 3 nM) but was inactive (Ki > 10,000 nM) in 37 other receptor/neurotransmitter-uptake/enzyme/transduction system binding assays, including those for alpha-bungarotoxin, muscarinic and 5-hydroxytryptamine3 receptors. In PC12 cells, patch-clamp studies indicated that ABT 418 was an agonist with an EC50 value of 209 microM, a potency to activate cholinergic channel currents some 4-fold less than that of (-)-nicotine (52 microM). Channel current responses elicited by ABT 418 were prevented by the cholinergic channel blocker, mecamylamine. ABT 418 was also approximately 10-fold less potent (EC50 value = 380 nM) than (-)-nicotine (40 nM) in increasing [3H]-dopamine release from rat striatal slices, an effect that was blocked by the nAChR antagonist, dihydro-beta-erythroidine (10 microM).2+ In contrast, ABT 418 appeared equipotent with (-)-nicotine in enhancing 86Rb+ flux from mouse thalamic synaptosomes. ABT 418 demonstrated an in vitro pharmacological profile of cholinergic channel activation that was robust at some nAChR, but not others. The reasons for this are unclear. However, a nAChR subtype selectivity may account for the in vitro potency differences of ABT 418 on various neurotransmitter systems, and the substantial separation between the cognitive enhancement/anxiolytic benefits, and the reduced central nervous system side-effect liabilities seen in vivo. ABT 418 represents the first neuronal nAChR ligand that differentiates the toxicities/liabilities and other negative aspects normally associated with liabilities and other negative aspects normally associated with (-)-nicotine from the potential pharmacological benefits of selective cholinergic channel activation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an α4β2 nAChR agonist, ABT-418, was found to increase open arm time in the EPM and both ABT-418 and an α4β2 nAChR partial agonist, ABT-089, reversed the anxiogenic effects of nicotine withdrawal (Brioni et al., 1994; Decker et al., 1994; Yohn, Turner, & Blendy, 2014).”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Decker et al., 1994
Citations
Cited by
Sorted by citations
Neuronal nicotinic receptors in the human brain
Paterson, D., & Nordberg, A. K. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00045-3 · Cited by 792
Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain
Picciotto, M. R., Zoli, M., Léna, C., Bessis, A., Lallemand, Y., LeNovère, N., Vincent, P., Pich, E. M., Brûlet, P., & Changeux, J.-P. (1995) · Nature · doi:10.1038/374065a0 · Cited by 668
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Nicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R. S., Rollema, H., & Bertrand, D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 543
Nicotinic acetylcholine receptors in health and disease
Lindstrom, J. (1997) · Molecular Neurobiology · doi:10.1007/bf02740634 · Cited by 443
Neuronal Nicotinic Acetylcholine Receptors
Lindstrom, J. (1996) · Springer eBooks · doi:10.1007/978-1-4899-1775-1_10 · Cited by 382
Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease
Wilkinson, D. G., Francis, P. T., Schwam, E. M., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 367
Paylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A., & Orr-Urtreger, A. (1998) · Learning & Memory · doi:10.1101/lm.5.4.302 · Cited by 298
“First, there are high levels of a7 containing nAChRs in the hippocampus (Dineley-Miller and Patrick 1992; Perry et al. 1993; Seguela et al. 1993; Court et al. 1995), a structure critical for the types of learning and memory affected by nicotine treatment (see Cohen and Eichenbaum 1993).”
BackgroundNicotinic System Involvement in Alzheimer??s and Parkinson??s Diseases
NEWHOUSE, P. A., Potter, A., & Levin, E. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711030-00005 · Cited by 266
Decker, M. W., Brioni, J. D., Bannon, A. W., & Arnerić, S. P. (1995) · Life Sciences · doi:10.1016/0024-3205(94)00488-e · Cited by 256
Self-citationDrug enhancement of memory consolidation: historical perspective and neurobiological implications
McGaugh, J. L., & Roozendaal, B. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1285-6 · Cited by 250
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1931 · Cited by 230
Jones, C. K., Byun, N. E., & Bubser, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.199 · Cited by 241
“…treatment of cognitive deficits associated with schizophrenia and other neurological disorders (see Table 5), including ABT-418, ABT-089, ABT-594, 5-iodo-A-85380, and TC-1734 (AZD3480; isopronicline) (Arneric et al, 1994; Decker et al, 1994b; Lin et al, 1997; Mukhin et al, 2000; Obinu et al, 2002).”
BackgroundVascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia.
Román, G. C., & Kalaria, R. N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.004 · Cited by 213
Neuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
Arendash, G. W., Sengstock, G. J., Sanberg, P. R., & Kem, W. R. (1995) · Brain Research · doi:10.1016/0006-8993(94)01449-r · Cited by 198
Balfour, D. J. K., & Fagerström, K. O. (1996) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00099-x · Cited by 194
Briggs, C., Anderson, D. J., Brioni, J., Buccafusco, J., Buckley, M., Campbell, J. E., Decker, M. W., Donnelly-Roberts, D., Elliott, R., Gopalakrishnan, M., et al. (1997) · Pharmacology, Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00354-1 · Cited by 190
Self-citationFile, S. E., Kenny, P. J., & Ouagazzal, A. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.6.1423 · Cited by 193
Central nicotinic receptors, neurotrophic factors and neuroprotection
Belluardo, N., Mudò, G., Blum, M., & Fuxé, K. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00197-2 · Cited by 176
5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors
Mukhin, A. G., Gündisch, D., Horti, A. G., Koren, A. O., Tamagnan, G., Kimes, A. S., Chambers, J., Vaupel, D. B., King, S. L., Picciotto, M. R., et al. (2000) · Molecular Pharmacology · doi:10.1124/mol.57.3.642 · Cited by 173
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163
“The lack of adverse sideeffects suggest that at least acutely, ABT-418 has a wider therapeutic index than nicotine, confirming previous animal studies (Decker et al. 1994).”
BackgroundResultInfluentialHuman α4β2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study
Buisson, B., Gopalakrishnan, M., Arnerić, S. P., Sullivan, J. P., & Bertrand, D. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07880.1996 · Cited by 183
“A good correlation exists between the high-affinity (2)-nicotine binding sites and the rodent brain regions expressing the a4 and b2 subunits (Clarke et al., 1985; Deutch et al., 1987; Swanson et al., 1987; Marks et al., 1992).”
BackgroundSelf-citationSensitization of the Mesoaccumbens Dopamine Response to Nicotine
Balfour, D. J. K., Benwell, M. E. M., Birrell, C. E., Kelly, J. T., & Al-Aloul, M. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00537-6 · Cited by 157
Meyer, E. M., Tay, E. T., Papke, R. L., Meyers, C., Huang, G., & de Fiebre, C. M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00536-2 · Cited by 158
Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms
Mudó, G., Belluardo, N., & Fuxe, K. (2006) · Journal of neural transmission · doi:10.1007/s00702-006-0561-z · Cited by 125
Sarter, M. F., & Bruno, J. P. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.011 · Cited by 150
“The potency of ACh to dilate cerebral blood vessels appears to be mediated via M5 muscarinic [216] and nicotinic receptors [40,44,102,208] .”
BackgroundThe Pharmacology of (-)-Nicotine and Novel Cholinergic Channel Modulators
Brioni, J. D., Decker, M. W., Sullivan, J. P., & Arnerić, S. P. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60950-3 · Cited by 134
Self-citationSullivan, J. P., Donnelly‐Roberts, D. L., Briggs, C. A., Anderson, D. J., Gopalakrishnan, M., Piattoni-Kaplan, M., Campbell, J. E., McKenna, D. G., Molinari, E., Hettinger, A.-M., et al. (1996) · Neuropharmacology · doi:10.1016/0028-3908(96)84644-2 · Cited by 137
Self-citationAttentional effects of nicotinic agonists in rats
Hahn, B., Sharples, C. G. V., Wonnacott, S., Shoaib, M., & Stolerman, I. P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00099-6 · Cited by 135
Daly, J. W., Garraffo, H. M., Spande, T. F., Decker, M. W., Sullivan, J. P., & Williams, M. J. (2000) · Natural Product Reports · doi:10.1039/a900728h · Cited by 131
Self-citationMcGaughy, J., Decker, M. W., & Sarter, M. (1999) · Psychopharmacology · doi:10.1007/s002130050991 · Cited by 128
Self-citationStevens, K. E., & Wear, K. D. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00466-2 · Cited by 129
nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanisms
Sarter, M., Parikh, V., & Howe, W. M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.019 · Cited by 123
Degroot, A., & Treit, D. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02965-7 · Cited by 123
Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update
Hoskin, J. L., Al-Hasan, Y. M., & Sabbagh, M. N. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty116 · Cited by 128
Nicotinic Receptors in Neurodegeneration
Posadas, I., López‐Hernández, B., & Ceña, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030005 · Cited by 116
Gatto, G. J., Bohme, G. A., Caldwell, W. S., Letchworth, S. R., Traina, V. M., Obinu, M. C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., et al. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00010.x · Cited by 111
Graef, S., Schönknecht, P., Sabri, O., & Hegerl, U. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2153-8 · Cited by 107
“For instance, passive avoidance performance has been linked to the α4β2* subtype (Decker et al. 1994b; Lippiello et al. 1996).”
BackgroundPharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes
Wilkie, G., Hutson, P. H., Sullivan, J. P., & Wonnacott, S. (1996) · Neurochemical Research · doi:10.1007/bf02532425 · Cited by 103
Self-citationIn vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418
Donnelly‐Roberts, D. L., Xue, I. C., Arnerić, S. P., & Sullivan, J. P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00063-7 · Cited by 101
Self-citationNegative affective states and cognitive impairments in nicotine dependence
Hall, F. S., Der‐Avakian, A., Gould, T. J., Markou, A., Shoaib, M. C., & Young, J. W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.06.004 · Cited by 110
Donnelly‐Roberts, D. L., Puttfarcken, P. S., Kuntzweiler, T. A., Briggs, C. A., Anderson, D. J., Campbell, J. E., Piattoni-Kaplan, M., McKenna, D. G., Wasicak, J. T., Holladay, M. W., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37422-1 · Cited by 103
Self-citationFile, S. E., Gonzalez, L. E., & Andrews, N. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.2.352 · Cited by 115
Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
Decker, M. W., & Meyer, M. D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00122-7 · Cited by 102
Self-citationBuccafusco, J. J., Jackson, W. J., Terry, A. V., Marsh, K. C., Decker, M. W., & Arnerić, S. P. (1995) · Psychopharmacology · doi:10.1007/bf02311172 · Cited by 100
Self-citationPrendergast, M., Jackson, W. J., Terry, A. V., Decker, M. W., Arnerić, S. P., & Buccafusco, J. J. (1998) · Psychopharmacology · doi:10.1007/s002130050538 · Cited by 99
Self-citationNicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders
Kutlu, M. G., & Gould, T. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.029 · Cited by 97
Turek, J. W., Kang, C. H., Campbell, J. E., Arnerić, S. P., & Sullivan, J. P. (1995) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(95)00032-p · Cited by 91
Self-citationCognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 94
Decker, M. W., Bannon, A. W., Curzon, P., Gunther, K. L., Brioni, J. D., Holladay, M. W., Lin, N.-H., Li, Y., Daanen, J. F., Buccafusco, J. J., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37015-6 · Cited by 88
Self-citationHuman α 7 nicotinic acetylcholine receptor responses to novel ligands
Briggs, C. A., McKenna, D. G., & Piattina-kaplan, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00028-5 · Cited by 88
Development of ligands for in vivo imaging of cerebral nicotinic receptors
Sihver, W., Nordberg, A. K., Långström, B., Mukhin, A. G., Koren, A. O., Kimes, A. S., & London, E. D. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00209-6 · Cited by 86
Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats
Turchi, J. N., Holley, L. A., & Sarter, M. F. (1995) · Psychopharmacology · doi:10.1007/bf02245840 · Cited by 83
Modeling Alzheimer's disease with non-transgenic rat models
Lecanu, L., & Papadopoulos, V. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt171 · Cited by 83
Wonnacott, S., & Gallagher, T. C. (2006) · Marine Drugs · doi:10.3390/md403228 · Cited by 82
Sullivan, J. P., Donnelly‐Roberts, D. L., Briggs, C. A., Anderson, D. J., Gopalakrishnan, M., Xue, I. C., Piattoni-Kaplan, M., Molinari, E. J., Campbell, J. E., McKenna, D. G., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37014-4 · Cited by 79
Self-citationNeurotrophic effects of central nicotinic receptor activation
Belluardo, N., Mudò, G., Blum, M., Amato, G., & Fuxé, K. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_15 · Cited by 75
Reinforcing Effects of Nicotinic Compounds Intravenous Self-administration in Drug-Naive Mice
Rasmussen, T. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00003-3 · Cited by 71
“062 (mmol/kg) that was demonstrated to improve learning and memory in mouse passive avoidance (10).”
BackgroundInfluentialEffects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats
Decker, M. W., Curzon, P., Brioni, J. D., et al. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90323-9 · Cited by 72
Self-citationSociety for Research on Nicotine and Tobacco
Heishman, S. J., Balfour, D. J. K., Benowitz, N. L., Hatsukami, D. K., Lindstrom, J. M., & Ockene, J. K. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb02919.x · Cited by 71
Tani, Y., Saito, K., Imoto, M., & Ohno, T. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00314-8 · Cited by 69
Nicotine addiction and psychiatric disorders
Kutlu, M. G., Parikh, V., & Gould, T. J. (2015) · International Review of Neurobiology · doi:10.1016/bs.irn.2015.08.004 · Cited by 65
“For example, an α4β2 nAChR agonist, ABT-418, was found to increase open arm time in the EPM and both ABT-418 and an α4β2 nAChR partial agonist, ABT-089, reversed the anxiogenic effects of nicotine withdrawal (Brioni et al., 1994; Decker et al., 1994; Yohn, Turner, & Blendy, 2014).”
BackgroundKenny, P. J., Cheeta, S., & File, S. E. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00114-8 · Cited by 63
Decker, M. W., Bannon, A. W., Buckley, M. J., et al. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00042-9 · Cited by 62
Self-citationSullivan, J. P., & Bannon, A. W. (1996) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1996.tb00288.x · Cited by 60
Self-citationGABAergic Systems Modulate Nicotinic Receptor-Mediated Seizures in Mice
Dobelis, P., Hutton, S. R., Lü, Y., & Collins, A. C. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053066 · Cited by 58
Preclinical research into cognition enhancers
Sarter, M. F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.004 · Cited by 59
Bontempi, B., Whelan, K. T., Risbrough, V. B., Rao, T. S., Buccafusco, J. J., Lloyd, G. K., & Menzaghi, F. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29330-7 · Cited by 56
Bain, E., Robieson, W., Pritchett, Y., Garimella, T., Abi-Saab, W., Apostol, G., McGough, J., & Saltarelli, M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.194 · Cited by 50
“Selective agonists of the a4b2 NNRs produce procognitive effects in animal models of cognition (Buccafusco et al, 1995; Decker et al, 1994; Grottick and Higgins, 2000).”
Activation and inhibition of rat neuronal nicotinic receptors by ABT‐418
Papke, R. L., Thinschmidt, J. S., Moulton, B., Meyer, E. M., & Poirier, A. E. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700930 · Cited by 55
Pharmacological Characterization of SIB-1765F: A Novel Cholinergic Ion Channel Agonist
Sacaan, A. I., Reid, R. T., Santori, E. M., Adams, P., Correa, L. D., Mahaffy, L. S., Bleicher, L. S., Cosford, N. D. P., Stauderman, K. A., McDonald, I. A., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36402-x · Cited by 55
REVIEW: Cognitive effects of nicotine: genetic moderators
Herman, A. I., & Sofuoglu, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00213.x · Cited by 52
“Picciotto et al. (1995) reported that in b2nAChR KO mice, nicotine did not boost associative memory performance, an expected response in wild-type mice (Oliverio 1966; Decker et al. 1994).”
BackgroundLevandoski, M. M., Piket, B., & Chang, J. P. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01796-5 · Cited by 48
Bencherif, M., Schmitt, J. D., Bhatti, B. S., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37321-5 · Cited by 47
The Role of Nicotine in Schizophrenia
Featherstone, R. E., & Siegel, S. J. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.07.002 · Cited by 47
Tasso, B., Boido, C. C., Terranova, E., Gotti, C., Riganti, L., Clementi, F., Artali, R., Bombieri, G., Meneghetti, F., & Sparatore, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900225j · Cited by 42
Wall, P. M., & Messier, C. (2000) · Brain Research · doi:10.1016/s0006-8993(99)01990-3 · Cited by 45
Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain
Sihver, W., Långström, B., & Nordberg, A. K. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00304.x · Cited by 45
“ABT-418, a nicotinic analog with the structure of an isoxazole, was initially developed as highly selective a4b2 ligand with cognitiveenhancing and anxiolytic properties (44, 45).”
BackgroundTC-2559: A novel orally active ligand selective at neuronal acetylcholine receptors
Bencherif, M., Bane, A. J., Miller, C. H., Dull, G. M., & Gatto, G. J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00807-4 · Cited by 44
Szyndler, J., Sienkiewicz‐Jarosz, H., Maciejak, P., Siemiątkowski, M., Rokicki, D., Członkowska, A., & Płaźnik, A. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00548-2 · Cited by 42
Chapter 5. Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry and Pharmacology
McDonald, I. A., Cosford, N. D. P., & Vernier, J. (1995) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60918-5 · Cited by 42
Holladay, M. W., Lebold, S. A., & Lin, N. (1995) · Drug Development Research · doi:10.1002/ddr.430350402 · Cited by 42
Nicotine: abused substance and therapeutic agent.
Houezec, J. L. (1998) · PubMed Central · Cited by 41
Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders
Terry, A. V., Callahan, P. M., & Hernandez, C. M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.027 · Cited by 40
“Initial discovery efforts lead to the identification of the α4β2 nAChR agonists ABT-418 [49] and SIB-1508Y [50] and the α7 nAChR agonists AR-R1779 [51] and GTS-21 (DMXBA); [52] with each nAChR subtype agonist displaying distinct neuropharmacological [49, 50, 53]; and behavioral [52, 54-59] effects thereby supporting t…”
Obinu, M. C., Reibaud, M., Miquet, J.-M., Pasquet, M., & Rooney, T. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00205-1 · Cited by 40
The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia
Sienkiewicz‐Jarosz, H., Członkowska, A. I., Siemiątkowski, M., Maciejak, P., Szyndler, J., & Planik, A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070004 · Cited by 40
“…of the muscarinic and nicotinic receptors may modulate in a selective way animal behaviour in pre-clinical models of anxiety (Brioni et al., 1993; Decker et al., 1994, 1995; Rodgers et al., 1995; Smythe et al., 1996; File et al., 1998a,b; Smythe et al., 1998), but contribution of these two types…”
BackgroundArnerić, S. P., Anderson, D. J., Bannon, A. W., Briggs, C. A., Buccafusco, J. J., Brioni, J. D., Cannon, J. B., Decker, M. W., Donnelly‐Roberts, D. L., Gopalakrishnan, M., et al. (1995) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1995.tb00274.x · Cited by 40
Self-citationNew isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates
Silva, N. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01327-7 · Cited by 39
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET
Mitkovski, S., Villemagne, V. L., Novakovic, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Mulligan, R. S., Dickinson, K. L., Saunder, T., Grégoire, M., Bottlaender, M., et al. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.04.013 · Cited by 39
Nirogi, R. V. S., Goura, V., Abraham, R., & Jayarajan, P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.021 · Cited by 40
Mechanisms of GABAergic and cholinergic neurotransmission in auditory thalamus: Impact of aging
Richardson, B. D., Sottile, S. Y., & Caspary, D. M. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108003 · Cited by 37
Treatment of dementia with neurotransmission modulation
Doggrell, S. A., & Evans, S. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1633 · Cited by 44
Rasmussen, T., Fink‐Jensen, A., Sauerberg, P., Swedberg, M. D. B., Thomsen, C., Sheardown, M. J., Jeppesen, L., Calligaro, D. O., DeLapp, N. W., Whitesitt, C. A., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00129-8 · Cited by 37
Rollema, H., & Hurst, R. S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4921-9 · Cited by 42
Chalyk, B. A., Kandaurova, I. Y., Hrebeniuk, K. V., et al. (2016) · RSC Advances · doi:10.1039/c6ra02365g · Cited by 34
Mazurov, A. A., Miao, L., Bhatti, B. S., Strachan, J., Akireddy, S. R., Murthy, S. M., Kombo, D. C., Xiao, Y.-D., Hammond, P., Zhang, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3006542 · Cited by 35
Belluardo, N., Mudò, G., Blum, M., Cheng, Q., Caniglia, G., Dell’Albani, P., & Fuxé, K. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00266-1 · Cited by 34
Pharmacological treatment of cognitive dysfunction in dementia disorders
Nordberg, A. K. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb00379.x · Cited by 33
Nicotinic Receptors and Attention
Hahn, B. (2015) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-13665-3_5 · Cited by 33
Metadata
- Authors
- Decker, M. W., Brioni, J. D., Sullivan, J. P., Buckley, M. J., Radek, R. J., Raszkiewicz, J. L., Kang, C. H., Kim, D. J., Giardina, W. J., & Wasicak, J. T.
- Affiliations
- Abbott (United States) (US)
- ORCID
- Decker, M W
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 270
- Issue
- 1
- Pages
- 319-328
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2100773070
- Cited by
- 180
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2020: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 8 · 2014: 1 · 2013: 6 · 2012: 6
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- ABT-418, cognitive enhancement, anxiolytic effects, avoidance learning, mecamylamine, elevated plus maze, cortical EEG, cholinergic ligands
- MeSH terms
- Quinolizidine Alkaloids, Alkaloids, Animals, Azocines, Binding, Competitive, Cognition, Corpus Striatum, Dopamine, Ion Channels, Isoxazoles, Kinetics, Male, Nicotine, Parasympathomimetics, Pyrrolidines, Quinolizines, Receptors, Cholinergic, Receptors, Nicotinic, Rubidium, Rubidium Radioisotopes, Anti-Anxiety Agents, Tritium, PC12 Cells, Rats, Sprague-Dawley, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
